PulmOne

Company Overview

Snapshot

Founded in March 2006 by Avi Lazar, PulmOne operates with 51–200 employees. The company has raised $13.71 million across 5 funding rounds from 2 investors. In December 2021, Alpha LTI led a funding round for PulmOne.

Business overview

PulmOne develops patient-friendly and budget-conscious devices designed to accurately inform clinical decision-making for respiratory diseases. Its core products, the MiniBox and MiniBox+, are desktop systems for measuring lung volume, spirometry, and diffusing capacity (DLCO), providing a complete pulmonary function testing solution without relying on a plethysmograph or external gas source. The company serves the healthcare industry, including hospitals, clinics, and healthcare providers, operating within the Health Tech & Life Sciences sector, specifically focusing on medical devices, diagnostics, and monitoring.

Strategic signal

In November 2019, PulmOne announced the integration of FeNO by NIOX® with its MiniBox+ system. This strategic enhancement allows for the measurement of fractional exhaled nitric oxide, a key biomarker for airway inflammation, directly within their comprehensive pulmonary function testing platform. This move signals PulmOne's commitment to expanding the diagnostic capabilities of its devices, offering a more complete solution for respiratory disease management and potentially increasing its market appeal to clinicians seeking advanced, integrated diagnostic tools.

Company Intelligence Q&A

What is PulmOne's primary focus?

PulmOne focuses on developing patient-friendly and budget-conscious devices for accurate clinical decision-making in the diagnosis, treatment, and monitoring of respiratory diseases.

What is the MiniBox+?

The MiniBox+ is PulmOne's comprehensive system that adds a diffusing capacity (DLCO) module to the spirometry and lung volume measurement (LVM) tests offered by the MiniBox, providing a complete pulmonary function testing solution.

When was PulmOne founded?

PulmOne was founded in March 2006 by Avi Lazar.

What was a key product enhancement announced by PulmOne in November 2019?

In November 2019, PulmOne began offering FeNO by NIOX® with its MiniBox+ Complete Pulmonary Function Testing System, enhancing its diagnostic capabilities.

What is the purpose of PulmOne's devices?

PulmOne's devices are designed to accurately inform clinical decision-making for respiratory diseases, offering patient-friendly and budget-conscious solutions.